

**RESIGNATION OF CHIEF EXECUTIVE OFFICER**

TALi Digital Ltd (ASX:TD1, "TALi" or "the Company"): The Board of TALi Digital Limited advises that Mr Glenn Smith has tendered his resignation as Managing Director and Chief Executive Officer of the Company effective 31 March 2022.

Mr Smith has advised his resignation is a decision related to his desire to focus on other priorities. Mr Smith said: "I am exceptionally proud of what my team and I have achieved this far and excited about what the future holds for the business. Now is the right time for me to handover to the new executive team and importantly the outlook for the business is extremely positive."

Commenting on Mr Smith's decision, the Company's Chair, Ms Sue MacLeman, remarked: "We understand and respect the reasons for Mr Smith's decision to resign. We wish him well for the future."

In the coming months the Board will undertake a search for a new Chief Executive Officer to succeed Mr Smith and, in the interim, Ms MacLeman, with support from the rest of the Board, will take on the added responsibility.

**Release authorised by:**

The Board of TALi Digital Limited

**CONTACT****Corporate**

Sue MacLeman  
Chair  
TALi Digital  
0437 211 200  
investors@talidigital.com

**Investors**

Paul McKeon  
Investor Relations Manager  
TALi Digital  
1300 082 013  
investors@talidigital.com

## About TALi Digital

TALi Digital Limited (ASX: TD1) is a digital health company delivering diagnostic and therapeutic solutions to enhance cognitive function and behaviour. The Company has built a patented platform technology with our first solution targeting cognitive attention skills during early childhood via the evidence-based screening (DETECT®) and training (TRAIN®) modules. This program is complementary to existing diagnosis and therapy, placing TALi at the forefront of improving early intervention for childhood attention and concentration performance. We believe in healthy, happier minds – our vision is to deliver a personalised digital experience to enhance cognitive care.

A continuous innovation focus will see the Company deliver a series of product developments in ADHD (Attention Deficit Hyperactivity Disorder) and ASD (Autism Spectrum Disorder). Learn more at [talidigital.com](https://talidigital.com).